MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC
Reason given: Low accrual, close out in November 2025
Key facts
- Where
- Heidelberg and Munich, GermanySee the 2 sites
- Phase
- Phase 2
Where in Germany
- University Hospital of Heidelberg, Dep. of Radiation OncologyHeidelberg, GermanyNo longer taking part
- University of Munich, Dep. of Radiation OncologyMunich, GermanyNo longer taking part
Trial details
- Who runs it
- Ludwig-Maximilians - University of Munich
- Trial code
- NCT05114213
- Record updated
- 5 December 2025
- Original description
The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients with metastatic PDAC (mPDAC).Read full original descriptionShow less
MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - a Randomized, Controlled Clinical Study
The MASPAC trial investigates the added benefit of MR-guided adaptive SBRT of the primary tumor embedded between standard chemotherapy cycles for pain control and prevention of pain in patients with metastatic PDAC (mPDAC).
Inclusion: Male and female patients with histologically proven, metastatic pancreatic adenocarcinoma of the pancreatic head or body amenable for MR-guided adaptive SBRT with at least stable disease after 8 weeks of standard of care doublet chemotherapy; age >18 years; Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2; Ability to follow study instructions and likely to attend and complete all required visits.
Exclusion: Simultaneous participation in another clinical study or participation in any clinical trial involving an investigational medicinal product or treatment within 30 days prior to beginning of this study; Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the study results, or may interfere with the subject's participation in this study; Subjects not able to give consent; Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical study; Women of child bearing potential or sexually active males not willing to use effective contraception while on treatment and 12 weeks after the end of treatment (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases; Biopsy proven tumor invasion into the stomach and/or duodenum; Medically uncontrolled pain.